| Título: | Is Quality of Life Data Predictive of the Survival in Cancer Patients? A Rapid and Systematic Review of the Literature |
| Autores: | Montazeri, Ali |
| Fecha: | 2012-04-17 |
| Publicador: | Shahid Beheshti University of Medical Sciences |
| Fuente: |
Ver documento |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | No aplica |
| Descripción: | AbstractObjective: To review literature on relationship between quality of life data and the length of survival in cancer patients.Methods: A literature search was carried out using MEDLINE to assess existing knowledge on relationship between quality of life data as a prognostic factor and survival in cancer patients. The intention was to review all full publications in English language biomedical journals. The search strategy included the combination of keywords ‘cancer’, ‘prognostic’, ‘predictor’, ‘predictive’, ‘quality of life’ and ‘survival’ in titles of publications. The literature was also examined to ensure that the study used multivariate analyses. Pure psychological studies were excluded. The initial search was carried out twice in December 2008 and twice for a final check in early and late January 2009. A manual search also was performed for including possible additional papers.Results: In all 146 citations were identified and reviewed. Of these, 88 citations on relationship between quality of life and survival were found relevant and examined in this rapid and systematic review of the literature. The findings are summarized under different headings including studies on heterogeneous sample of cancer patients, lung cancer, breast cancer, gastro-oesophageal cancers, colorectal cancer and other cancers. Except a few exceptions most studies found that quality of life data or some aspects of quality of life measures were significant independent predictors of survival duration. Global quality of life, functioning domains and symptom scores such as appetite loss, fatigue and pain individually or in combined were the most important factors that predicted the length of survival in cancer patients after adjusting for one or more demographic and known clinical prognostic factors.Conclusion: Studies reported in this review provide evidence for a positive relationship between quality of life data or some aspects of quality of life measures and the length of survival in cancer patients. Pre-treatment quality of life data are appeared to be most reliable information that could help clinicians to establish prognostic criteria for treatment of their cancer patients. Indeed, conducting studies using valid instruments, applying sound methodological approaches and adequate but not sophisticated multivariate statistical analyses adjusted for demographic characteristics and known clinical prognostic factors are recommended in order to yield more specific quality of life related prognostic variables for specific cancers.Keywords: quality of life, prognostic factor, predicting factor, survival, cancer, patient-reported outcomesReferences1. Montazeri A, Gillis CR, McEwen J. Measuring quality of life in oncology: is it worthwhile? Part I. Meaning, purposes, and controversies. Eur J Cancer Care.1996; 5: 159-167.2. Montazeri A, Gillis CR, McEwen J. Measuring quality of life in oncology: is it worthwhile? Part II. Experiences from the treatment of cancer. Eur J Cancer Care. 1996; 5: 168-175.3. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. How quality of life data contribute to our understanding of cancer patients’ experiences? A study of patients with lung cancer. Qual Life Res.2003; 12: 157-166.4. Montazeri A, McEwen J, Gillis CR. Quality of life in patients with ovarian cancer: the current state of the research. Support Care Cancer.1996; 4: 169-179.5. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest.1998; 113: 467-481.6. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic of the literature from 1974 to 2007. J Exp Clin Cancer res .2008; 27: 32.7. Pater JL, Loeb M. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Cancer.1982; 50: 326-331.8. Cassileth BR, Lusk EJ, Miller DS, Brown LL, Miller C. Psychosocial correlates of survival in advanced malignant disease? N Engl J Med.1985; 312: 1551-555.9. Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MH,et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategy. N Engl J Med.1987; 317: 1490-1495.10. Kaasa S, Mastekaasa A, Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being. Radiother Oncol.1989; 15: 235-242.11. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage.1995; 10: 423-431.12. Ringdal GI, Götestam KG, Kaasa S, Kvinnsland S, Ringdal K. Prognostic factors and survival in a heterogeneous sample of cancer patients. Br J Cancer.1996; 73: 1594-1599.13. Tamburini M, Brunelli C, Rosso S, Ventafridda V. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage .1996; 11: 32-341.14. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer .1997; 33: 1025-1030.15. Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res.1997; 6: 151-158.16. Chang VT, Thaler HT, Polyak TA, Kornblith AB, Lepore JM, Portenoy RK.Quality of life and survival: the role of multidimensional symptom assessment. Cancer.1998 83: 173-179.17. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer.Cancer.1991; 67: 3131-3135.18. Ruckdeschel JC, Piantadosi S. Quality of life in lung cancer surgical adjuvant trial. Chest.1994; 106: 324-328.19. Loprinzi CL, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW, Bartel J, et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol.1994; 12: 601-607.20. Buccheri GF, Ferrigno D, Tamburini M, Brunelli C. The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer. Lung Cancer.1995; 12: 45-58.21. Buccheri G. Depressive reactions to lung cancer are common and often followed by a poor outcome. Eur Respir J.1998; 11: 173-178.22. Herndon JE 2nd, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer.1999; 85: 333-340.23. Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol. 2000; 55: 19-25.24. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer.2001; 31: 233-240.25. Auchter RM, Scholtens D, Adak S, Wanger H, Cella DF, Mehta MP. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Int J Radiat Oncol Biol Phys.2001; 50: 1199-1206.26. Moinpour CM, Lyons B, Grevstad PK, Lovato LC, Growley J, Czaplicki K, Buckner ZM, et al. Quality of life in advanced non-small-cll lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res.2002; 11: 115-126.27. Nakahara Y, Mochizuki Y, Miyamoto Y, Tanaka A, Kawamura T, Sasaki S, Nakahara Y, Katsura Y. Mental state as a possible independent prognostic variable for survival in patients with advanced lung carcinoma. Cancer.2002; 94: 3006-3015.28. Naughton MJ, Herndon JE, Shumaker SA, Miller AA, Kornblith AB, Chao D, Hollan J. The health – related quality of life and survival of small-cell lung cancer patients: Results of a companion study to CALGB 9033. Qual Life Res.2002; 11: 235-248.29. Etom DT, Fairclough DJ, Cella D, Yount SE, Bonomi P, Johnson DH. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from eastern cooperative oncology group study 5592. J Clin Oncol.2003; 21: 1536-1543.30. Dharma-Wardene M, Au HJ, Hanson J, Dupere D, Hewitt J, Feeny D. Baseline FACT-G score is a predictor of survival for advanced lung cancer. Qual Life Res. 2004; 13: 1209-1216.31. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol.2004; 22: 3172-3180.32. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol.2005; 23: 6865-6872.33. Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MK, et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol.2005; 23: 7417-727.34. Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, et al. the EORTC Lung Cancer Group and Quality of Life Unit. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol.2006; 17: 1698-1704.35. Sundstrøm S, Bremnes RM, Brunsvig P, Aasebø U, Kaasa S.Norwegian Lung Cancer Study Group. Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? J Thorac Oncol.2006; 1: 816-824.36. Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, et al. EORTC-NCIC.Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol.2007; 25: 5770-5776.37. Fielding R, Wong WS. Quality of life as a predictor of cancer survival among Chinese liver and lung cancer patients. Eur J Cancer.2007; 43: 1723-1730.38. Jacot W, Colinet B, Bertrand D, Lacombe S, Bozonnat MC, Daurès JP, Pujol JL.OncoLR health network. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol 2008; 19: 1458-1464.39. Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byne M, Forbes JF.Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trial Group. J Clin Oncol.1992, 10: 1833-1838.40. Fraser SC, Ramirez AJ, Ebbes SR, Fallowfield LJ, Dobbs HJ, Richards MA, Bates T, et al. A daily diary for quality of life measurement in advanced breast cancer trials. Br J Cancer.1993; 67: 341-346.41. Seidman AD, Portenoy R, Yao TJ, Lepore J, Mont EK, Kortmansky J, Onetto N, et al: Quality of life in phase II trials-A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel, plus granulocyte colony stimulating factor. J Natl Cancer Inst.1995; 187: 1316-1322.42. Tross S, Herndon J, Korzun A, Kornblith AB, Cella DF, Herndon JF, Raich P, et al.From the Cancer and Leukemia Group B. psychosocial smptome and disease – free and overall survival in women with stage II breast cancer. J Natl Cancer Inst.1996; 88: 661-667.43. Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancer.1999 16: 1331-1336.44. Coates AS, Hurny C, Peterson HF, Bernhard J, Castinglione-Gertsch M, Gelberg D, Goldhirsch A: Quality of life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol.2000, 18: 3768-3774.45. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning PF, Klijn JG, van Hoorebeeck I,et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer.2000, 36: 1498-1506.46. Shimozuma K, Sonoo H, Ichihara K, Tanaka K: The prognostic value of quality of life scores: preliminary results of an analysis of patients with breast cancer. Surg Today.2000; 30: 255-261.47. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survical: Metastatic breast cancer. Ann Oncol.2000; 11: 469-474.48. Luoma ML, Hakamies-Blomqvist L, Sjostrom J, Pluzanska A, Ottoson S, Mouridsen H, Bengtsson NO, et al. Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer.2003, 39: 1370-1376.49. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol.2004; 22: 2061-2068.50. Efficace F, Therasse P, Piccart MJ, Coens C, van Steen K, Welnicka-Jaskiewicz M, Cufer T, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol.2004; 22: 3381-3388.51. Efficace F, Biganzoli L, Piccart M, Coens C, van Steen K, Cufer T, Coleman RE, et al. Baseline health-related quality of life data as prognostic factors in a phase III multicenter study of women with metastatic breast cancer. Eur J Cancer.2004; 40: 1021-1030.52. Goodwin PJ, Ennis M, Bordeleau LJ, Pritchard KT, Trudeau Me, Koo J, Hood N. Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables. J Clin Oncol.2004; 22: 4184-4192.53. Watson M, Homewood J, Haviland J, Bliss J. Influence of psychosocial response on breast cancer survival: 10-year follow-up of a population-based cohort. European Journal of Cancer.2005, 41: 1710-1714.54. Lehto US, Ojanen M, Dyba T, Aromaa A, Kellokumpu Lehtinen P. Baseline psychosocial predictors of survival in localized breast cancer. Br J Cancer.2006; 94: 1245-1252.55. Gupta D, Granick J, Grutsch JF, Lis CG. The prognostic association of health-related quality of life scores with survival in breast cancer. Support Care Cancer.2007; 15: 387-393.56. Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychosocial distress and fatigue predicted recurrence and survival in primary breast cancer patients. Br J Cancer.2007; 105: 209-219.57. Blazeby JM, Brookes ST, Alderson D. Prognostic value of quality of life scores in patients with oesophageal cancer. Br J Surg.2000; 87:362-373.58. Blazeby JM, Brookes ST, Alderson D. The prpognostic value of quality of life scores during treatment for oesophageal cancer. Gut.2001; 49: 227-230.59. Fang FM, Tsai WL, Chiu HC, Kuo WR, Hsiung CY.Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2004; 58: 1394-1404.60. Chau I, Norman AR, Cunningham D, Waters JS, Oates J. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer: pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol.2004; 2395-2403.61. Park SH, Cho MS, Kim YS, Hong J, Nam E, Park J, Cho EK, et al . Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. Qual Life Res.2008; 17: 207-214.62. Bergquist H, Johnsson A, Hammerlid E, Wenger U, Lundell L, Ruth M. Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation. Aliment Pharmacol Ther.2008; 27: 385-395.63. McKernan M, Mcmillan Dc, Anderson JR, Angerson WJ, Stuart RC. The relationship between quality of life (EORT QLQ-C30) and survival in patients with gastro-oesophageal cancer. J Clin Oncol.2008; 98: 888-893.64. Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol.1996; 14: 171-175.65. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer.2002; 38: 1351-1357.66. Lis CG, Gupta D, Granick J, Grutsch JF. Can patient satisfaction with quality of life predict survival in advanced colorectal cancer? Support Care Cancer.2006; 14: 1104-1110.67. Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H,et al. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer.2006; 42: 42-49.68. Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D. Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol.2008; 26: 2020-2026.69. Cassileth BR, Walsh WP, Lusk EJ. Psychosocial correlates of cancer survival: a subsequent report 3 to 8 years after cancer diagnosis. J Clin Oncol.1988; 6: 1753-1759.70. Coates A, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, Kefford R, et al. Prognostic value of quality of life scores in a trial of Chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer.1993; 29: 1731-1734.71. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol.1996; 14: 1753-1755.?72. Wisløff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol.1997; 97: 29-37.73. De Boer MF, Van den Borne B, Pruyn JF, Ryckman RM, Volovics L, Knegt PP, Meeuwis CA,et al. Psychosocial and physical correlates of survival and recurrence in patients with head and neck carcinoma: results of a 6-year longitudinal study. Cancer.1998; 83:2567-2579.74. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol.1999; 17: 2256.75. Brown JE, Butow PN, Culjak G, Coates AS, Dunn SM. psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma. Br J Cancer.2000; 83: 1448-1453.76. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as predictor of survival in patients with recurrent malignant glioma. J Clin Oncol.2000; 18: 646-650.77. de Graeff A, de Leeuw JR, Row WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer.2001; 37: 332-339.78. Jerkeman M, Kaasa S, Hjermstad M, Kvaløy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol.2001;18: 85-94.79. Roychowdhury DF, Hayden A, Liepa AM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol.2003; 21: 673-678.80. Chiarion-Sileni V, Del Bianco P, De Salvo GL, Lo Re G, Romanini A, Labianca R, Nortilli R, et al. Italian Melanoma Intergroup (IMI). Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer.2003; 39:1577-1585.81. Fang FM, Liu YT, Tang Y, Wang CJ, Ko SF. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer.2004; 100: 425-432.82. Collette L, Andel GA, Bottomley A, Oosterhof G, Albrecht W, Rrijke TM. Is baseline quality of life useful for predicting survival with hormone-Refractory prostate cancer? A pooled Analysis of three studies of the European organization for research and treatment of cancer genitourinary Group. J Clin Oncol.2004; 22: 3877-3885.83. Monk BJ, Huang HQ, Cella D, Long HJ, Gynecologic oncology Group study. Quality of life outcome from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol.2005; 23: 4617-4625.84. Brown PD, Ballman KV, Rummans TA, Maurer MJ, Sloan JA, Boeve BF, Gupta L, et al. Prospective study of quality of life adults with newly diagnosed high-grade gliomas. J Neurooncol.2006; 76: 283-291.85. Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, Chan L, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol.2006; 17: 1083-1089.86. Lis CG, Gupta D, Grutsch JF.Patient satisfaction with quality of life as a predictor of survival in pancreatic cancer. Int J Gastrointest Cancer.2006; 37: 35-44.87. Dubois D, Dhawan R, Van de velde H, Esseltine D, Gupta S, Viala M, Loge C. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol.2006; 24: 976-982.88. Sullivan PW, Nelson JB, Mulani PM, Sleep D. Quality of life as potential predictor morbidity and mortality in patients with metastastic hormone-refratory prostate cancer. Qual Life Res.2006; 15: 1297-1306.89. Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, Brandes AA, et al. EORTC Brain Cancer Group. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol.2007; 25: 5731-5737.90. Mauer M, Stupp R, Taphoorn MJ, Coens C, Osoba D, Marosi C, Wong R, et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer.2007; 97: 302-307.91. Lehto US, Ojanen M, Dyba T, Aromaa A, Kellokumpu Lehtinen P. Baseline psychosocial predictors of survival in localized melanoma. J Psychosom Res.2007; 63: 9-15.92. Bonnetain F, Paoletti X, Collette S, Doffoel M, Bouché O, Raoul JL, Rougier P,et al. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res.2008; 17: 831-843.93. Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol Oncol.2008; 108: 100-105.94. Gupta D, Grutsch JF, Lis CG. Patient satisfaction with quality of life as a prognostic indicator in ovarian cancer patients treated in an integrative treatment setting. J Soc Integr Oncol.2008; 6: 98-104.95. Gotay CC, Kawamoto CT, Bottomoley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol.2008; 26: 1355-1363.96. Van Steen K, Curran D, Kramer J, Molenberghs G, Van Verckem A, Bottomley A, Sylvester R. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med.2002; 21: 3865-3884.97. Bottomley A, Efficace F. Predicting survival in advanced cancer patients: is it possible with patient-reported health status data? Ann Oncol.2006; 17: 1037-1038. |
| Idioma: | Inglés |
1 Health and Education - 2 por Akbari, Mohammad Esmaeil | 6 Effectiveness of Mindfulness-Based Cognitive Therapy on Reduction of Depression and Anxiety Symptoms in Mothers of Children With Cancer por Mehranfar, Mojtaba; Dept. of Counselling, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,Younesi, Jalal; Dept. of Counselling, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,Banihashem, Abdollah; Dept. of Internal Medicine and Paediatrics, University of
Medical Sciences, Mashhad, Iran |
2 The Study of DNA Methylation of bax Gene Promoter in Breast and Colorectal Carcinoma Cell Lines por Alipour, Mohsen; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Zargar, Seyed Jalal; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Safarian, Shahrokh; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Fouladdel, Shamile; Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran,Azizi, Ebrahim; Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran,Jafargholizadeh, Naser; Dept. of Cell & Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran | 7 Prevention and Management of Mucositis in Patients With Cancer: a Review Article por [wlia, ّatemeh; Dept. of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran,«azemeini, ُeidkazem; Burn hospital, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran,gholami, neda; Dept. of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran |
3 Cancer Prevention; Cancer Risk Management por Akbari, Mohammad Esmaeil | 8 Psychosocial Care for Breast Cancer: Physicians' Perspective por Kaviani, Ahmad; Department of surgery, Tehran University of Medical Sciences, Tehran, Iran,Mehrdad, N; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Yunesian, M; school of Public Health , Environmental Research Center, Tehran University of Medical Sciences, Tehran, Iran,Shakiba, B; Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran,Ebrahimi, M; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Majidzadeh, K; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Akbari, ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
4 Euthanasia in Cancer Patients, Islamic Point of View por Mousavi, SM; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Akbari, A; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Akbari, ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Najd Sepas, H; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran | 9 Cell Survival Entropy and Cellular Resistance Activation Dose: Effect of Calprotectin on Gastric Adenocarcinoma Cell Line por Rezaei-Tavirani, Mostafa,Rahmati-Roodsari, Mohammad,Mirzaie, Mehdi,Amini Geram, Pooneh,Sobhi, Sara |
5 Evaluation of Prognostic Factors In Patients with Metastatic Breast Cancer por Saeidi Saedi, H,Seilanian Toosi, M,Mirsadraei, M,Roodbari, S | 10 Antiphospholipid Antibodies in Neoplastic Patients por Mortazavizadeh, MR,Sadeghmanesh, R |